SCHEMBL1103087

SCHEMBL1103087

c1ccc2c(-c3c4ccccc4c(-c4ccc(-c5ccc(-c6c7ccccc7c(-c7cccc8ccccc78)c7ncccc67)cc5)cc4)c4cccnc34)cccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
MAPT P10636 6/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 4/20 0.42
HSD17B10 Q99714 3/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
CCR1 P32246 3/20 0.41
CCR8 P51685 3/20 0.41
LMNA P02545 3/20 0.41
CYP3A4 P08684 2/20 0.41
TP53 P04637 2/20 0.41
GMNN O75496 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MMP2 P08253 1/20 0.41
CYP2D6 P10635 1/20 0.41
MMP9 P14780 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103184 0.97 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103102 0.96 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103198 0.95 KDM4E (0.41) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103095 0.94 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103211 0.92 PIM1 (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103218 0.91 COMT (0.46) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103117 0.91 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1103000 0.91 KDM4E (0.42) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL1102865 0.90 KDM4E (0.47) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL13512523 0.90 KDM4E (0.50) KDM4EMAPTALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885MAPT 3162/4885ALDH1A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.